Delivering the Added Dimension in Drug Discovery Services
Jubilant Biosys, a subsidiary of Jubilant Pharmova, is a leading contract research organization in India and provides innovative drug discovery services to the global pharmaceutical industry through our locations across India and the USA. Jubilant Pharmova achieved over $1,293m revenue for FY20.
As a partner in drug discovery and development services, Jubilant Biosys offers unique and specialized support that bridges the entire drug discovery process. If you are looking for quality solutions incorporated with the best practices in the drug discovery domain, feel free to contact us.
Jubilant offers integrated drug discovery services spanning across Hit Identification/Target Validation (HI/TV) to Lead Optimization (LO)/Pre-clinical Candidate (PCC), for multiple therapeutic areas. With well enabled capabilities in oncology, metabolic disorders, CNS, pain, inflammation, fibrosis and respiratory diseases, Jubilant, as an integrated preclinical CRO, has rapidly emerged as a leading collaborator for biotechnology and pharmaceutical companies worldwide.
In each of these therapeutic areas, Jubilant has developed in-depth expertise in discovery informatics, computational chemistry / molecular modelling, medicinal chemistry, structural biology, in-vivo pharmacology and in-vitro pharmacology and translational sciences.
In the drug discovery process, the team focuses on early stage lead generation across various target classes and uses a wide range of technologies, including high throughput screening, molecular modelling, medicinal chemistry, structural biology and computational chemistry, to identify novel start points that are then selectively taken through the pre-clinical discovery process. Our expertise in animal pharmacology with multiple PD and disease models enabled, help us deliver IND candidates.
Jubilant operates on a customized approach offering innovative solutions across the drug discovery value chain to the biotechnology and pharmaceutical industry. To suit each client’s requirements in the best possible manner, we offer flexibility through the following business models:
Jubilant collaborates with the world’s leading pharmaceutical and biotech companies, academic institutions and research foundations. Innovative and rigorous science, excellence in execution, and absolute integrity, combined with flexible business models has enabled Jubilant to deliver valuable outcomes in a relatively short period of time. The hallmark of Jubilant’s collaborative model is the creation of value to partners.